Skip to content

Clinical trials

Phase 2 Central Nervous System Diseases trials in Canada

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Central Nervous System Diseases Phase: Phase 2 Country / region: Canada Clear all

13 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20103
20161
20181
20191
20201
20221
20232
20252
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed7
Recruiting3
Active, not recruiting1
Terminated1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
GlaxoSmithKline2
Bial R&D Investments, S.A.1
Eli Lilly and Company1
Inmune Bio, Inc.1
MapLight Therapeutics1
Neuraltus Pharmaceuticals, Inc.1
Novartis1
Novartis Pharmaceuticals1
Ron Postuma1
Takeda1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Central Nervous System Diseases13
Brain Diseases10
Nervous System Diseases10
Neurodegenerative Diseases7
Alzheimer Disease6
Dementia5
Mental Disorders4
Movement Disorders3
Parkinson Disease3
Parkinsonian Disorders3

Trials

Showing 1 to 13 of 13. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.